title: ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.
abstract: Amyloid-beta1-42 (Abeta1-42) is crucial to Alzheimer disease (AD) pathogenesis but the conformation of the toxic Abeta species remains uncertain. AD risk is increased by apolipoprotein E4 (apoE4) and decreased by apoE2 compared with the apoE3 isoform, but whether inheritance of apoE4 represents a gain of negative or a loss of protective function is also unresolved. Using hippocampal slices from apoE knockout (apoE-KO) and human apoE2, E3, and E4 targeted replacement (apoE-TR) mice, we found that oligomeric Abeta1-42 inhibited long-term potentiation (LTP) with a hierarchy of susceptibility mirroring clinical AD risk (apoE4-TR > apoE3-TR = apoE-KO > apoE2-TR), and that comparable doses of unaggregated Abeta1-42 did not affect LTP. These data provide a novel link among apoE isoform, Abeta1-42, and a functional cellular model of memory. In this model, apoE4 confers a gain of negative function synergistic with Abeta1-42, apoE2 is protective, and the apoE-Abeta interaction is specific to oligomeric Abeta1-42.
authors.affiliation: Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60614, USA. btrommer@northwestern.edu
authors.forename: Barbara L
authors.initials: BL
authors.lastname: Trommer
authors.forename: Chirag
authors.initials: C
authors.lastname: Shah
authors.forename: Sung Hwan
authors.initials: SH
authors.lastname: Yun
authors.forename: Georgi
authors.initials: G
authors.lastname: Gamkrelidze
authors.forename: Emily S
authors.initials: ES
authors.lastname: Pasternak
authors.forename: W Blaine
authors.initials: WB
authors.lastname: Stine
authors.forename: Arlene
authors.initials: A
authors.lastname: Manelli
authors.forename: Patrick
authors.initials: P
authors.lastname: Sullivan
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Pasternak
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: LaDu
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics* / Q000378:metabolism* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D017774:Long-Term Potentiation / Q000187:drug effects / Q000235:genetics*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008970:Molecular Weight; D018696:Neuroprotective Agents / Q000378:metabolism / Q000494:pharmacology; D009924:Organ Culture Techniques; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D011487:Protein Conformation; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D020033:Protein Isoforms; C075222:amyloid beta-protein (1-42)